Key facts
- This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for Evommune, Inc..
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Nov 2025, 16:26.
RA CAPITAL MANAGEMENT, L.P. - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- EVMN on NYSE
- Reported as of
- 07 Nov 2025
- Net transaction value
- +$20,000,000
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2025, 16:26:30 UTC
- Prior SEC filing
- 05 Nov 2025
- Next SEC filing
- 14 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RA CAPITAL MANAGEMENT, L.P. filed Form 4 for Evommune, Inc. on 12 Nov 2025.
Change
- Previous filing in this sequence was filed on 05 Nov 2025.
- Current net transaction value: +$20,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001346824
Primary reporting owner
RA CAPITAL MANAGEMENT, L.P.
- Relationship
- Director, 10%+ Owner
- Address
- 200 BERKELEY STREET, 18TH FLOOR, BOSTON
- Signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
- Signature date
- 12 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,517,329
- Change %
- Price
- Shares after
- 1,517,329
- Date
- 07 Nov 2025
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +691,441
- Change %
- Price
- Shares after
- 691,441
- Date
- 07 Nov 2025
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F4
EVMN
transaction
Common Stock
Purchase
- Transaction value
- $18,513,536
- Shares
- +1,157,096
- Change %
- +76%
- Price
- $16.00
- Shares after
- 2,674,425
- Date
- 07 Nov 2025
- Ownership
- See Footnotes
- Footnotes
- F2, F3
EVMN
transaction
Common Stock
Purchase
- Transaction value
- $1,486,464
- Shares
- +92,904
- Change %
- +13%
- Price
- $16.00
- Shares after
- 784,345
- Date
- 07 Nov 2025
- Ownership
- See Footnotes
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -12,924,620
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,517,329
- Exercise price
- Footnotes
- F1, F2, F3
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -5,889,699
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 691,441
- Exercise price
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date.
Footnote F2
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
Footnote F3
Held directly by the Fund.
Footnote F4
Held directly by the Nexus Fund III.
SEC remarks
Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.